As per Global Insight services’ assessment, about 20+ prominent pharma and biotech giants are working on 20+ drugs in the Diabetic Retinopathy – Drug Pipeline Landscape, 2023 globally. Diabetic Retinopathy – Drug Pipeline Landscape, 2023 report by Global Insight Services provides a comprehensive analysis of the ongoing clinical development activities and growth prospect.
“Download PDF Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key –https://www.globalinsightservices.com/request-sample/GIS31255
Diabetic retinopathy is a censorious medical disorder that affects the eyes due to inefficient insulin level in the blood of the patient. A high sugar level in the blood causes blockage of the retina’s small blood capillaries, impeding blood flow resulting in cloudy or blurred vision. There are two types of diabetic retinopathy non-proliferative diabetic retinopathy and proliferative diabetic retinopathy.
A high sugar level in the blood causes blockage of the retina’s small blood capillaries and impairment to blood vessels of the light-sensitive tissue of the retina is the main cause of diabetic retinopathy.
Symptoms of diabetic retinopathy are blurred vision, dark or empty spots in the vision, fluctuating vision, poor colour identification and vision loss.
Diabetic retinopathy is diagnosed by a comprehensive dilated eye exam and Fluorescein angiography.
Diabetic retinopathy is treated by diet modifications and drugs like insulin vascular endothelial growth factor inhibitors and laser treatment, eye surgery.
Free customization available –https://www.globalinsightservices.com/request-customization/GIS31255
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Diabetic Retinopathy treatment such as KSI-301, LY-09004, RTH258 and others. Key players involved in the development of therapies to treat Diabetic Retinopathy are Bayer, Boehringer Ingelheim, F. Hoffmann-La Roche AG, Hengenix Biotech Inc, OcuTerra Therapeutics Inc and others. Seven drugs are under late-stage Phase III clinical trials and sixteen drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.
In October 2022, OcuTerra published safety and biological activity data of OTT166 from phase 1b study in diabetic eye disease.
Report Highlights
Global Insight Service’s, Diabetic Retinopathy – Drug Pipeline Landscape, 2023 report provides an overview of the Diabetic Retinopathy pipeline drugs. This report covers detailed insights on Diabetic Retinopathy drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Diabetic Retinopathy pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Buy your copy now: https://www.globalinsightservices.com/checkout/single_user/GIS31255
Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like
– Late-stage products (Phase III)
– Mid-stage products (Phase II)
– Early-stage product (Phase I)
– Pre-clinical and Discovery stage candidates
– Discontinued & Inactive candidates
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1–833–761–1700
Website: https://www.globalinsightservices.com/